Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Novartis AG ADR

USUSD
← Allo screener

Novartis AG ADR (SW:NOVNEE) — Drug Manufacturers - General. Numero di borse in cui sono quotate le azioni della società: 6. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'azienda

Sito web
novartis.com
Settore
Healthcare · Drug Manufacturers - General
Sede centrale
BASEL, Switzerland
Amministratore delegato
Dr. Vasant Narasimhan M.D.
Dipendenti
75 267
Fondata
1996
Azioni in circolazione
1.91 Mld al 2025-12-31
Flottante
1.86 Mld
Capitalizzazione di mercato
276.48 Mld USD
Insider
0.01%
Investitori istituzionali
7.27%
Settore (SIC)
Pharmaceutical Preparations
Forma giuridica
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Payout ratio
71.1%
FCF
15.0 Mld USD
61%
Debito
49.0 Mld USD
2.6 anni di FCF
Serie di dividendi
20 a.
Descrizione

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Borse e ticker

BorsaTickerValutaPrezzoTipo
US USA StocksNVSEFUSD134.22 -0.23%azioni ordinarie
MI Borsa Italiana (Milan)1NOVNEUR127.28 +1.50%azioni ordinarie
SW SIX Swiss ExchangeNOVNCHF119.8 -0.13%azioni ordinarie
SW SIX Swiss ExchangeNOVNEECHF120.02 -1.80%azioni ordinarie
VI Vienna Stock ExchangeNOVNEUR126.72azioni ordinarie
XETRA XetraNOTEUR126.82 +0.48%azioni ordinarie

Prezzo su 3 mesi

giorno di rialzo giorno di ribasso data di stacco del dividendo data di pagamentoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo

Dividendi

Ultimi 12 mesi, US:NVSEF: 3.7 CHF (1 pag.)

Novartis AG ADR (NVSEF) paga dividendi in modo irregolare. Negli ultimi 12 mesi, sono stati pagati 3.7 CHF per azione (pagamenti: 1). In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 11.03.2027. Storia dei dividendi ininterrotta: 20 anni.

Data exPagamentoImporto%TipoTicker
2026-03-112026-03-123.7000 CHF3.3/3.3 %annualeUS:NVSEF

Notizie di questa settimana

Ancora nessuna notizia dal sito della società.

pubblicità

Principali azionisti

DetentoreQuotaAzioniData del rapporto
Fisher Asset Management,…0.76%15.52 Mln2026-06-30
Morgan Stanley0.43%8.73 Mln2026-06-30
Dimensional Fund Advisor…0.4%8.12 Mln2026-06-30
Primecap Management Comp…0.32%6.59 Mln2026-06-30
LOOMIS SAYLES & CO L P0.26%5.24 Mln2026-06-30
Bank of America Corporat…0.24%4.91 Mln2026-06-30
VANGUARD CHESTER FUNDS-V…0.21%4.25 Mln2026-06-30
Franklin Resources, Inc.0.16%3.25 Mln2026-06-30
Blackrock Inc.0.15%3.05 Mln2026-06-30
Goldman Sachs Group Inc0.15%2.98 Mln2026-06-30
Northern Trust Corporati…0.14%2.79 Mln2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 Mln2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 Mln2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 Mln2026-06-30
Franklin Mutual Series F…0.06%1.19 Mln2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30